(Q54719166)

3 June 2018

title

Cardiovascular toxicity of molecularly targeted agents. (English)

1 reference

3 June 2018

1 reference

Elizabeth L Strevel

1

1 reference

3 June 2018

Lillian L Siu

series ordinal

2

1 reference

3 June 2018

publication date

1 September 2009

1 reference

3 June 2018

European Journal of Cancer

published in

1 reference

3 June 2018

volume

45 Suppl 1

1 reference

3 June 2018

page(s)

318-331

1 reference

3 June 2018

New targets, therapies, and toxicities: lessons to be learned

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Vascular effects of aromatase inhibitors: data from clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

High blood pressure. A side effect of drugs, poisons, and food.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Tumor angiogenesis: therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Differentiation of endothelial cells: analysis of the constitutive and activated endothelial cell phenotypes

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Vascular Endothelium as the Vulnerable Element in Tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Motesanib diphosphate in progressive differentiated thyroid cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Terminal ballistics of kinase inhibitors: there are no magic bullets

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

The role of nitric oxide in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Exaggerated hypotensive effect of vascular endothelial growth factor in spontaneously hypertensive rats

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Capillary rarefaction and abnormal cardiovascular reactivity in hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Mechanisms of hypertension associated with BAY 43-9006.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Reversible posterior leukoencephalopathy syndrome and bevacizumab

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Incidence of cardiovascular disease and cancer in advanced age: prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Prognostic importance of comorbidity in a hospital-based cancer registry

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Home blood-pressure monitoring in patients receiving sunitinib

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Randomized trials of sodium reduction: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Chemotherapy agents and hypertension: a focus on angiogenesis blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Cardiotoxicity of Cancer Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Cardiac effects of adjuvant therapy for early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Cardiac toxicity: old and new issues in anti-cancer drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

ErbB2 is essential in the prevention of dilated cardiomyopathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Requirement for neuregulin receptor erbB2 in neural and cardiac development

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Cardiac dysfunction in the trastuzumab clinical trials experience

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Trastuzumab-induced cardiomyopathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Bre

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Cardiac toxicity of sunitinib

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Trastuzumab-associated cardiotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

The evaluation of left ventricular function for patients being considered for, or receiving Trastuzumab (Herceptin) therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 G

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Effect of Arsenic Trioxide on QT Interval in Patients With Advanced Malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Timing of new black box warnings and withdrawals for prescription medications

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Comparison of formulae for heart rate correction of QT interval in exercise ECGs from healthy children

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

A comparison of commonly used QT correction formulae: the effect of heart rate on the QTc of normal ECGs.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Sudden deaths following influenza vaccination: can this be expected?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Predicting drug-hERG channel interactions that cause acquired long QT syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Molecularly targeted oncology therapeutics and prolongation of the QT interval

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

Challenges of evaluating the cardiac effects of anticancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

A phase II study of depsipeptide in refractory metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970046-2

7 January 2021

10.1016/S0959-8049(09)70046-2

Identifiers

DOI

1 reference

3 June 2018

1 reference

3 June 2018